Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
about
Molecular predictive markers in tumors of the gastrointestinal tractSingle-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel.A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomasThe Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-AnalysisThe distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors.Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus.The role of cell-free DNA in predicting colorectal cancer prognosis.Future perspectives of circulating tumor DNA in colorectal cancer.Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology.Role of circulating free DNA in colorectal cancer.Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Elevated Cell-Free DNA Measured by a Simple Assay Is Associated With Increased Rate of Colorectal Cancer Relapse.Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancerUsefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations.
P2860
Q28070583-416393D2-DFE6-4B6C-B7EE-FBB224741D64Q35877954-E9B9B71A-4430-424C-AC61-DA7756711731Q35884196-4E27F49B-21AA-4816-BF9C-DF3BD6E17772Q36091092-32E52210-6A6B-479B-AF54-F1E3E79420B9Q37015727-44FFA807-31C7-4C7E-871A-2D30A682CF34Q38481038-2D156930-D8E2-4064-88B9-72B5E4C47E6BQ38580566-795AA44C-6C3E-4A44-A9F2-B0D5C43484D5Q38637642-00E102D5-533A-489D-8690-7F4C99951F64Q38685749-D7F771ED-D4AD-443C-84B0-0ED80136C945Q38697494-6B1D46A9-C897-40B8-9262-C8F711B4D50EQ38800475-544684AD-7718-4138-9D7E-DC704FB23202Q39051652-F6F72F0A-38A8-4730-ABC1-19F0613A86FEQ39051797-61BEDA61-4226-4131-8815-DA43DC19671EQ39149201-69041E73-F5FB-4AC4-9943-E2000FAC81A5Q40716508-864FE1E7-CE8C-4508-B39A-8F46A9D9C0CAQ41547611-5B0F84F1-81FD-4062-A863-01DF6F9DB0D9Q41862850-4CBC1A0A-F042-4E61-B808-83E551E62465Q47563363-FBE6CA9E-76C7-4ABC-A067-0729CEC3428CQ49922743-270E4C26-2845-4C53-BA3E-3ED0E3AB057CQ53482447-F8076275-06C3-419D-ADBC-C8D0184625B6
P2860
Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@ast
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@en
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@nl
type
label
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@ast
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@en
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@nl
prefLabel
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@ast
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@en
Changes in mutational status d ...... , KRAS and BRAF in the plasma.
@nl
P2860
P356
P1476
Changes in mutational status d ...... A, KRAS and BRAF in the plasma
@en
P2093
Karen-Lise Garm Spindler
Niels Pallisgaard
P2860
P304
P356
10.1002/IJC.28863
P577
2014-04-17T00:00:00Z